| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Department of Adult Oncology and Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115
Flavopiridol, a synthetic flavone that inhibits tumor growth in vitro and in vivo, is a potent cyclin-dependent kinase (cdk) inhibitor presently in clinical trials. In the present study, the effect of 100–500 nM flavopiridol on a panel of non-small cell lung cancer cell lines was examined. All express a wild-type retinoblastoma susceptibility protein and lack p16INK4A, and only A549 cells are known to express wild-type p53. During 72 h of treatment, flavopiridol was shown to be cytotoxic to all seven cell lines, as measured by trypan blue exclusion, regardless of whether cells were actively cycling. In most cycling cells, cytotoxicity was preceded or accompanied by cell cycle arrest. Cell death resulted in the appearance of cells with a sub-G1 DNA content, suggestive of apoptosis, which was confirmed by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay and by demonstration of cleavage of caspase targets including poly(ADP-ribose) polymerase, p21Waf1, and p27Kip1. At doses at or below 500 nM, maximal cytotoxicity required 72 h of exposure. Although flavopiridol resulted in the accumulation of p53 in A549 cells, flavopiridol-mediated apoptosis was p53 independent because it occurred to the same degree in A549 cells in which p53 was targeted for degradation by HPV16E6 expression. The data indicate that flavopiridol has activity against non-small cell lung cancers in vitro and is worthy of continued clinical development in the treatment of this disease.
This article has been cited by other articles:
|
|
 |
|
  T. Budak-Alpdogan, B. Chen, A. Warrier, D. J. Medina, D. Moore, and J. R. Bertino Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma Clin. Cancer Res., February 15, 2009; 15(4): 1232 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Rao, P. Bhoopathi, C. Chetty, M. Gujrati, and S. S. Lakka MMP-9 Short Interfering RNA Induced Senescence Resulting in Inhibition of Medulloblastoma Growth via p16INK4a and Mitogen-Activated Protein Kinase Pathway Cancer Res., May 15, 2007; 67(10): 4956 - 4964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kobayashi, T. Shimamura, S. Monti, U. Steidl, C. J. Hetherington, A. M. Lowell, T. Golub, M. Meyerson, D. G. Tenen, G. I. Shapiro, et al. Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling Cancer Res., December 1, 2006; 66(23): 11389 - 11398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gizatullin, Y. Yao, V. Kung, M. W. Harding, M. Loda, and G. I. Shapiro The Aurora Kinase Inhibitor VX-680 Induces Endoreduplication and Apoptosis Preferentially in Cells with Compromised p53-Dependent Postmitotic Checkpoint Function. Cancer Res., August 1, 2006; 66(15): 7668 - 7677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. I. Shapiro Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cai, K. F. Byth, and G. I. Shapiro AZ703, an Imidazo[1,2-a]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9 Cancer Res., January 1, 2006; 66(1): 435 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne Inhibition of the Met Receptor in Mesothelioma Clin. Cancer Res., November 15, 2005; 11(22): 8122 - 8130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Vorburger, N. Hetrakul, W. Xia, M. Wilson-Heiner, N. Mirza, R. E. Pollock, B. Feig, S. G. Swisher, and K. K. Hunt Gene therapy with E2F-1 up-regulates the protein kinase PKR and inhibits growth of leiomyosarcoma in vivo Mol. Cancer Ther., November 1, 2005; 4(11): 1710 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shimamura, A. M. Lowell, J. A. Engelman, and G. I. Shapiro Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins Cancer Res., July 15, 2005; 65(14): 6401 - 6408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Brown Chronic Lymphocytic Leukemia: A Niche for Flavopiridol? Clin. Cancer Res., June 1, 2005; 11(11): 3971 - 3973. [Full Text] [PDF]
|
|
|
|
|
|
M. Puppo, S. Pastorino, G. Melillo, A. Pezzolo, L. Varesio, and M. C. Bosco Induction of Apoptosis by Flavopiridol in Human Neuroblastoma Cells Is Enhanced under Hypoxia and Associated With N-myc Proto-oncogene Down-Regulation Clin. Cancer Res., December 15, 2004; 10(24): 8704 - 8719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I. Shapiro Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Clin. Cancer Res., June 15, 2004; 10(12): 4270S - 4275S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. N. Demidenko and M. V. Blagosklonny Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor Cancer Res., May 15, 2004; 64(10): 3653 - 3660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Rosato, J. A. Almenara, C. Yu, and S. Grant Evidence of a Functional Role for p21WAF1/CIP1 Down-Regulation in Synergistic Antileukemic Interactions between the Histone Deacetylase Inhibitor Sodium Butyrate and Flavopiridol Mol. Pharmacol., March 1, 2004; 65(3): 571 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jiang, C. B. Matranga, D. Cai, V. M. Latham Jr., X. Zhang, A. M. Lowell, F. Martelli, and G. I. Shapiro Flavopiridol-Induced Apoptosis during S Phase Requires E2F-1 and Inhibition of Cyclin A-Dependent Kinase Activity Cancer Res., November 1, 2003; 63(21): 7410 - 7422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Litz, P. Carlson, G. S. Warshamana-Greene, S. Grant, and G. W. Krystal Flavopiridol Potently Induces Small Cell Lung Cancer Apoptosis during S Phase in a Manner That Involves Early Mitochondrial Dysfunction Clin. Cancer Res., October 1, 2003; 9(12): 4586 - 4594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. V. Oleinik and S. A. Krupenko Ectopic Expression of 10-Formyltetrahydrofolate Dehydrogenase in A549 Cells Induces G1 Cell Cycle Arrest and Apoptosis Mol. Cancer Res., June 1, 2003; 1(8): 577 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Nguyen, W. D. Schrump, W. S. Tsai, A. Chen, J. H. Stewart IV, F. Steiner, and D. S. Schrump Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling pathway J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1132 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-M. Kim, S.-Y. Koo, K. Jeon, M. H. Kim, J. Lee, C. Y. Hong, and S. Jeong Rapid Induction of Apoptosis by Combination of Flavopiridol and Tumor Necrosis Factor (TNF)-{alpha} or TNF-related Apoptosis-inducing Ligand in Human Cancer Cell Lines Cancer Res., February 1, 2003; 63(3): 621 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alonso, C. Tamasdan, D. C. Miller, and E. W. Newcomb Flavopiridol Induces Apoptosis in Glioma Cell Lines Independent of Retinoblastoma and p53 Tumor Suppressor Pathway Alterations by a Caspase-independent Pathway Mol. Cancer Ther., February 1, 2003; 2(2): 139 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ma, W. D. Cress, and E. B. Haura Flavopiridol-induced Apoptosis Is Mediated through Up-Regulation of E2F1 and Repression of Mcl-1 Mol. Cancer Ther., January 1, 2003; 2(1): 73 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Jarred, M. Keikha, C. Dowling, S. J. McPherson, A. M. Clare, A. J. Husband, J. S. Pedersen, M. Frydenberg, and G. P. Risbridger Induction of Apoptosis in Low to Moderate-Grade Human Prostate Carcinoma by Red Clover-derived Dietary Isoflavones Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1689 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Janne, M. L. Taffaro, R. Salgia, and B. E. Johnson Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma Cancer Res., September 15, 2002; 62(18): 5242 - 5247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Matranga and G. I. Shapiro Selective Sensitization of Transformed Cells to Flavopiridol-induced Apoptosis following Recruitment to S-Phase Cancer Res., March 1, 2002; 62(6): 1707 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Rosato, J. A. Almenara, L. Cartee, V. Betts, S. P. Chellappan, and S. Grant The Cyclin-dependent Kinase Inhibitor Flavopiridol Disrupts Sodium Butyrate-induced p21WAF1/CIP1 Expression and Maturation while Reciprocally Potentiating Apoptosis in Human Leukemia Cells Mol. Cancer Ther., February 1, 2002; 1(4): 253 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I. Shapiro, J. G. Supko, A. Patterson, C. Lynch, J. Lucca, P. F. Zacarola, A. Muzikansky, J. J. Wright, T. J. Lynch Jr., and B. J. Rollins A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer Clin. Cancer Res., June 1, 2001; 7(6): 1590 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Daniel, J. Duffield, T. Brunner, K. Steinmann-Niggli, N. Lods, and H.-P. Marti Matrix Metalloproteinase Inhibitors Cause Cell Cycle Arrest and Apoptosis in Glomerular Mesangial Cells J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 57 - 68. [Abstract] [Full Text]
|
|
|
|
|
|
R. W. Robey, W. Y. Medina-Pérez, K. Nishiyama, T. Lahusen, K. Miyake, T. Litman, A. M. Senderowicz, D. D. Ross, and S. E. Bates Overexpression of the ATP-binding Cassette Half-Transporter, ABCG2 (MXR/BCRP/ABCP1), in Flavopiridol-resistant Human Breast Cancer Cells Clin. Cancer Res., January 1, 2001; 7(1): 145 - 152. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. V. Achenbach, E. P. Slater, H. Brummerhop, T. Bach, and R. Müller Inhibition of Cyclin-Dependent Kinase Activity and Induction of Apoptosis by Preussin in Human Tumor Cells Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2794 - 2801. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Grimison, T. A. Langan, and R. A. Sclafani p16Ink4a Tumor Suppressor Function in Lung Cancer Cells Involves Cyclin-dependent Kinase 2 Inhibition by Cip/Kip Protein Redistribution Cell Growth Differ., October 1, 2000; 11(10): 507 - 515. [Abstract] [Full Text]
|
|
|
|
|
|
F. Innocenti, W. M. Stadler, L. Iyer, J. Ramírez, E. E. Vokes, and M. J. Ratain Flavopiridol Metabolism in Cancer Patients Is Associated with the Occurrence of Diarrhea Clin. Cancer Res., September 1, 2000; 6(9): 3400 - 3405. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. V. Achenbach, R. Muller, and E. P. Slater Bcl-2 Independence of Flavopiridol-induced Apoptosis. MITOCHONDRIAL DEPOLARIZATION IN THE ABSENCE OF CYTOCHROME c RELEASE J. Biol. Chem., October 6, 2000; 275(41): 32089 - 32097. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
